Extracellular Volume Fraction Based on Cardiac Magnetic Resonance T1 Mapping: An Effective Way to Evaluate Cardiac Injury Caused by Cardiac Amyloidosis in Patients with Multiple Myeloma

被引:1
|
作者
Liu, Minghui [1 ]
Shao, Liang [1 ]
Yang, Zhaoxia [2 ]
Wang, Qian [1 ]
Wu, Balu [1 ]
Liu, Xiaoyan [1 ]
Yu, Yalan [1 ]
Huang, Tingting [1 ]
Wang, Meixing [1 ]
He, Yong [3 ]
Liu, Guohong [2 ]
Zhou, Fuling [1 ]
机构
[1] Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan 430071, Peoples R China
[2] Wuhan Univ, Dept Radiol, Zhongnan Hosp, Wuhan 430071, Peoples R China
[3] Wuhan Univ, Dept Nucl Med, Zhongnan Hosp, Wuhan 430071, Peoples R China
基金
中国国家自然科学基金;
关键词
MANAGEMENT; DIAGNOSIS;
D O I
10.1155/2022/3094933
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
permits reproduction any provided original properly Multiple myeloma (MM) is a hematological malignancy of plasma cell origin. Cardiac amyloidosis (CA) is a common form of heart damage caused by MM and is associated with a poor prognosis. This study was a prospective cohort study and was aimed at evaluating the clinical predictive value of extracellular volume fraction (ECV) based on cardiovascular magnetic resonance (CMR) T1 mapping for cardiac amyloidosis and cardiac dysfunction in MM patients. Fifty-one newly diagnosed MM patients in Zhongnan Hospital of Wuhan University were enrolled in the study. A total of 19 patients (19/51; 37.25%) developed CA. The basal ECV of CA group was significantly higher than that of the non-CA group (p < 0.01). Multivariate logistic regression analysis showed that basal ECV (OR = 1.551, 95% CI 1.084-2.219, p < 0.05) and LDH1 level (OR = 1.150, 95% CI 1.010-1.310, p < 0.05) were two independent risk factors for CA. Further study demonstrated that basal ECV in the heart failure group was significantly higher than that of the nonheart failure group (p < 0.01). Notably, ROC curve showed that basal ECV had a good predictive value for CA and heart failure, with AUC of 0.911 and 0.893 (all p < 0.01), and the best cutoff values of 38.35 and 37.45, respectively. Taken together, basal ECV is a good predictor of CA and heart failure for MM patients.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Extracellular volume by cardiac magnetic resonance T1 mapping in cardiac amyloidosis: validation with endomyocardial biopsy
    Duca, F.
    Kammerlander, A.
    Zotter-Tufaro, C.
    Aschauer, S.
    Schwaiger, M.
    Marzluf, B.
    Bonderman, D.
    Mascherbauer, J.
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 : S230 - S231
  • [2] Extracellular volume by cardiac magnetic resonance t1 mapping in cardiac amyloidosis: validation with endomyocardial biopsy
    Duca, F.
    Kammerlander, A.
    Zotter-Tufaro, C.
    Aschauer, S.
    Schwaiger, M.
    Marzluf, B.
    Bonderman, D.
    Mascherbauer, J.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1198 - 1198
  • [3] Cardiac Magnetic Resonance T1 Mapping in Cardiac Amyloidosis
    Duca, Franz
    Kammerlander, Andreas A.
    Panzenboeck, Adelheid
    Binder, Christina
    Aschauer, Stefan
    Loewe, Christian
    Agis, Hermine
    Kain, Renate
    Hengstenberg, Christian
    Bonderman, Diana
    Mascherbauer, Julia
    JACC-CARDIOVASCULAR IMAGING, 2018, 11 (12) : 1924 - 1926
  • [4] Cardiac magnetic resonance T1 mapping in cardiac amyloidosis
    Duca, F.
    Zotter-Tufaro, C.
    Kammerlander, A.
    Panzenboeck, A.
    Binder, C.
    Aschauer, S.
    Koschutnik, M.
    Loewe, C.
    Schoenbauer, R.
    Agis, Hermine
    Hengstenberg, C.
    Bonderman, D.
    Mascherbauer, J.
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 : 17 - 19
  • [5] Cardiac Magnetic Resonance T1 Mapping for Cardiac Amyloidosis The Best Way Forward
    Karamitsos, Theodoros D.
    Papanastasiou, Christos A.
    JACC-CARDIOVASCULAR IMAGING, 2020, 13 (01) : 81 - 82
  • [6] Validation of cardiac magnetic resonance T1 mapping in cardiac amyloidosis
    Duca, F.
    Zotter-Tufaro, C.
    Kammerlander, A. A.
    Panzenboeck, A.
    Aschauer, S.
    Boerries, B.
    Agis, H.
    Kain, R.
    Bonderman, D.
    Mascherbauer, J.
    EUROPEAN HEART JOURNAL, 2017, 38 : 846 - 846
  • [7] Validation of cardiac magnetic resonance T1 mapping in cardiac amyloidosis
    Duca, F.
    Zotter-Tufaro, C.
    Kammerlander, A.
    Panzenboeck, A.
    Aschauer, S.
    Boerries, B.
    Agis, H.
    Kain, R.
    Bonderman, D.
    Mascherbauer, J.
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 : S8 - S9
  • [8] Extracellular volume expansion in cardiac amyloidosis: validation of cardiac magnetic resonance T1 mapping against endomyocardial biopsy
    Duca, F. Franz
    Zotter-Tufaro, C.
    Kammerlander, A. A.
    Panzenboeck, A.
    Aschauer, S.
    Boerries, B.
    Agis, H.
    Kain, R.
    Bonderman, D.
    Mascherbauer, J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 184 - 185
  • [9] Extracellular Volume Fraction and Noncontrast T1 Mapping Using 1.5-T Cardiac MET in AL Cardiac Amyloidosis
    Lee, Ga Yeon
    Kim, Sung Mok
    Choe, Yeon Hyeon
    Jeon, Eun-Seok
    JOURNAL OF CARDIAC FAILURE, 2014, 20 (08) : S76 - S76
  • [10] Cardiac magnetic resonance T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy
    Lavall, D. Daniel
    Vosshage, N.
    Stoebe, S.
    Denecke, T.
    Hagendorff, A.
    Laufs, U.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 78 - 78